Wall Street brokerages predict that Affimed (NASDAQ:AFMD – Get Rating) will announce ($0.18) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Affimed’s earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.24). Affimed reported earnings of $0.01 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 1,900%. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Affimed will report full year earnings of ($0.79) per share for the current financial year, with EPS estimates ranging from ($1.11) to ($0.32). For the next year, analysts anticipate that the firm will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.20) to ($0.35). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Affimed.
Affimed (NASDAQ:AFMD – Get Rating) last issued its earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). Affimed had a negative return on equity of 40.66% and a negative net margin of 149.76%. The company had revenue of $11.82 million for the quarter, compared to analyst estimates of $10.30 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share.
Shares of Affimed stock traded down $0.01 on Monday, hitting $3.27. The company’s stock had a trading volume of 53,441 shares, compared to its average volume of 1,610,380. The company has a quick ratio of 3.19, a current ratio of 3.20 and a debt-to-equity ratio of 0.13. The firm has a fifty day moving average price of $4.02 and a 200-day moving average price of $4.76. Affimed has a 52-week low of $2.88 and a 52-week high of $9.45. The company has a market capitalization of $403.58 million, a P/E ratio of -5.74 and a beta of 2.49.
Several hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. lifted its stake in shares of Affimed by 93.6% in the fourth quarter. Point72 Asset Management L.P. now owns 11,855,151 shares of the biopharmaceutical company’s stock worth $65,440,000 after acquiring an additional 5,732,500 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Affimed by 47.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 2,846,200 shares of the biopharmaceutical company’s stock valued at $17,590,000 after buying an additional 916,189 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Affimed by 126.4% during the third quarter. Janus Henderson Group PLC now owns 1,192,364 shares of the biopharmaceutical company’s stock worth $7,375,000 after buying an additional 665,656 shares in the last quarter. Altium Capital Management LP bought a new stake in shares of Affimed in the third quarter worth $4,110,000. Finally, Pictet Asset Management SA raised its holdings in Affimed by 15.9% in the fourth quarter. Pictet Asset Management SA now owns 4,627,458 shares of the biopharmaceutical company’s stock valued at $25,544,000 after acquiring an additional 636,342 shares in the last quarter. Institutional investors and hedge funds own 63.47% of the company’s stock.
About Affimed (Get Rating)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.
- Get a free copy of the StockNews.com research report on Affimed (AFMD)
- Time to Ring the Register on Funko Stock
- Palo Alto Networks Bottoms But A Rebound May Not Be Coming
- Under Armor Stock is Getting Undervalued
- Stock Market Downgrades Are Dragging The S&P 500 Lower
- The Institutions Go Long Saia, Inc In Q2
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.